VC: Biolex leads with $36M in round 2

Email LinkedIn
Tools


Biolex leads with $36 million second round.

VENTURE CAPITAL

COMPANY

AMOUNT/ROUND

LEAD INVESTORS

DESCRIPTION

Biolex Therapeutics
Pittsboro, NC

$36 million
second round

Polaris Venture Partners

Locteron, a controlled-release formulation of recombinant human alfa interferon, is expected to enter Phase I clinical trials later this year.

TargeGen
San Diego

$30 million
third round

BB Biotech Ventures

TargeGen is focusing on the development of small molecule kinase inhibitors for the treatment of edema and angiogenesis related diseases.

Algeta
Oslo

$29 million
first round

HealthCap

The funds raised will support the continued development of the company's lead product candidate, Alpharadin, through its ongoing Phase II clinical trials and into pivotal Phase III trials as a potential new treatment for bone metastases arising from primary prostate cancer.

Inotek Pharmaceuticals
Beverly, MA

$25 million
second round

Pitango Venture Capital

Inotek has seven products in pre-clinical or clinical development targeting oncology, cardiovascular, and inflammatory diseases.

Xigen
Lausanne, Switzerland

$21 million
first round

Tilocor Life Sciences, Venture Incubator, Initiative Capital

Xigen will take its lead compound, XG-102, into the clinic in 2006 for the treatment of stroke.

OncoMed Pharmaceuticals
Mountain View, CA

$13.9 million
first round

Latterell Venture Partners, US Venture Partners

Research focuses on destroying cancer stem cells that spread to other tissues and seed the metastases that ultimately may claim the life of the patient.

SpinX Technologies
Geneva

$12.5 million
second round

Bio Fund Management

The funds raised will support the further development and initial commercialization of SpinX's "programmable microfluidics" platform to perform biological assays.

ISTO Technologies
St. Louis

$10 million
undisclosed

Zimmer Holdings

ISTO is developing cell-based therapies that team with the body's resources to heal, regenerate, and restore full function to damaged cartilage.

Allylix
Lexington, KY

$1.5 million
first round

Bluegrass Angels

Allylix is focused on the development and commercialization of terpenes, a class of natural chemicals found in plants.